198
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Entecavir: a step forward in combating hepatitis B disease

, MD
Pages 3095-3109 | Published online: 12 Nov 2008
 

Abstract

Background: Entecavir (ETV) is a potent deoxyguanosine nucleoside analog with a very good safety record. Objectives/methods: This review provides a comprehensive overview on the mechanism of action, pharmacodynamics, pharmacokinetics, clinical efficacy and safety of entecavir obtained through an extensive literature search. Results/conclusion: ETV inhibits all three steps of hepatitis B virus replication via entecavir – triphosphate, its intracellular active form, by dose-dependently competing with deoxyguanosine triphosphate for incorporation into DNA. Superior efficacy of ETV over lamivudine (LVD) has been shown in four double-blind, randomized controlled clinical trials encompassing a large cohort of treatment naive HBeAg-positive and HBeAg-negative patients and LVD-refractory HBeAg-positive patients. Prolongation of ETV treatment is associated with further improvement of efficacy. In treatment-naive patients, cumulative probability of ETV resistance and viral breakthrough after 5 years of treatment has been reported as 1.2 and 0.8%, respectively. ETV displays low cytotoxicity in proliferating cultured liver cell and has an excellent safety in clinical use.

Notes

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.